title: [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
abstract: Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters type 2 (SGLT2) inhibitors (gliflozins). After failure of a monotherapy with metformin (first pharmacological choice in type 2 diabetes), both may offer an alternative to the add-on of a sulphonylurea, especially in patients at risk of hypoglycaemia. However, the choice between a DPP-4 inhibitor and a SGLT2 inhibitor is not easy and should be oriented based upon the individual patient characteristics. The arguments in favour of one or another pharmacological class are discussed, considering a clinical case of a patient with coronary heart disease and type 2 diabetes not well controlled with metformin.
authors.affiliation: Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU de Liège, Site Sart Tilman, Liège, Belgique.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.affiliation: Service de Diabétologie, Nutrition et Maladies métaboliques, CHU de Liège, Site Sart Tilman, Liège, Belgique.
authors.forename: N
authors.initials: N
authors.lastname: Paquot
mesh_terms: D000368:Aged; D002755:Choice Behavior; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004501:Education, Medical; D004704:Endocrinology / Q000193:education; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use*; D008297:Male; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds
keywords:  Coronary heart disease ;  DPP4 inhibitor ;  Gliflozin ;  Gliptin ;  SGLT2 inhibitor ;  Type 2 diabetes ; Chronic kidney disease 